Quantification of Peripheral Blood iNKTs After Allogeneic Stem Cell Transplantation
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The transplantation of allogeneic haematopoietic stem cells (HSCs) can lead to serious complications after transplantation, such as graft-versus-host disease (GvHD), infections and relapse due to immunosuppression. Invariant NKT cells (iNKT cells) play a pivotal role in modulating the immune response and have been demonstrated to be instrumental in the pathogenesis of GvHD, cytomegalovirus (CMV) infection, and relapse. Their levels are associated with the development of these complications. This multicentre study aims to test the feasibility of standardising iNKT cell monitoring and to investigate the association between iNKT cell levels and post-transplant complications.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rozpoznanie: ostra białaczka szpikowa (nie wtórna)
- •Choroba w pełnej remisji w momencie przeszczepu
- •Ogólny stan zdrowia: dobrze funkcjonujący pacjent
- •Źródło komórek macierzystych: krew obwodowa
✗ Disqualifies
- •Wcześniejszy przeszczep szpiku
- •Niekontrolowana choroba nowotworowa
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 70 Years
- Last updated (source)
- August 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
University Hospital Pilsen
Pilsen, Czechia
Trial contact
Monika Holubová, MSc.
Lenka Lukášová, MD, MSc.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.